CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

NCT03504488 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
Triple Negative Breast Cancer
Melanoma
Head and Neck Cancer

Interventions

BIOLOGICAL: CAB-ROR2-ADC
BIOLOGICAL: PD-1 inhibitor

Sponsor

BioAtla, Inc.